Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
This study has been completed.
Medical Research Council
Information provided by:
National Cancer Institute (NCI)
First received: July 8, 2002
Last updated: December 18, 2013
Last verified: May 2007
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2008|
|Estimated Primary Completion Date:||No date given|
Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15;112(6):2248-60. doi: 10.1182/blood-2008-03-145128. Epub 2008 Jul 8.